THE NOVEL GALECTIN-3 INHIBITOR GB1211 REDUCES INFLAMMATION & FIBROSIS IN A RABBIT HIGH FAT DIET MODEL OF NASH & FIBROSIS

被引：0
|
作者：
Slack, Robert [1 ]
Comeglio, Paolo [2 ]
Filippi, Sandra [2 ]
Guarnieri, Giulia [3 ]
Cellai, Ilaria [3 ]
Adorini, Luciano [4 ]
Morelli, Annamaria [3 ]
Vignozzi, Linda [5 ]
Maggi, Mario [3 ]
机构：
[1] Galecto Biotech AB, Boston, MA USA
[2] Univ Florence, Dept Expt & Clin Biochem Sci Mario Serio, Florence, Italy
[3] Univ Florence, Florence, Italy
[4] Ist Nazl Biostrutture & Biosistemi, Rome, Italy
[5] Univ Florence, Sexual Med & Androl, Florence, Italy
来源：
HEPATOLOGY | 2023年 / 77卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
5042
引用
收藏
页码：E153 / E153
页数：1
相关论文
共 50 条
  • [1] THE GALECTIN-3 INHIBITOR GB1211 DOSE DEPENDENTLY REDUCES INFLAMMATION AND FIBROSIS IN A HIGH FAT DIET RABBIT MODEL OF NASH
    Holyer, Ian
    Zetterberg, Fredrik
    Vignozzi, Linda
    Filippi, Sandra
    Comeglio, Paolo
    Morelli, Annamaria
    Cellai, Ilaria
    Guarnieri, Giulia
    Maggi, Mario
    Slack, Robert
    HEPATOLOGY, 2023, 78 : S1221 - S1221
  • [2] The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis
    Comeglio, Paolo
    Guarnieri, Giulia
    Filippi, Sandra
    Cellai, Ilaria
    Acciai, Gabriele
    Holyer, Ian
    Zetterberg, Fredrik
    Leffler, Hakon
    Kahl-Knutson, Barbro
    Sarchielli, Erica
    Morelli, Annamaria
    Maggi, Mario
    Slack, Robert J.
    Vignozzi, Linda
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [3] GULLIVER-2 IS AN INNOVATIVE, HYBRID, HEPATIC IMPAIRMENT TRIAL OF THE ORAL GALECTIN-3 INHIBITOR GB1211
    Tonev, Dimitar Velkov
    Krastev, Zahariy
    Stefanova-Petrova, Diana
    Balabanska, Rozalina
    Lindmark, Bertil
    Smith, Becky
    Genov, Jordan
    HEPATOLOGY, 2022, 76 : S1146 - S1147
  • [4] Single-Dose Pharmacokinetics and Safety of the Oral Galectin-3 Inhibitor, Selvigaltin (GB1211), in Participants with Hepatic Impairment
    Aslanis, Vassilios
    Gray, Michael
    Slack, Robert J.
    Zetterberg, Fredrik R.
    Tonev, Dimitar
    Phung, De
    Smith, Becky
    Jacoby, Brian
    Schambye, Hans
    Krastev, Zahari
    Ungell, Anna-Lena
    Lindmark, Bertil
    CLINICAL DRUG INVESTIGATION, 2024, 44 (10) : 773 - 787
  • [5] Relative bioavailability and food effect of the galectin-3 inhibitor selvigaltin (GB1211) administered as a tablet in healthy participants (GALBA-1)
    Aslanis, Vassilios
    Abd-Elaziz, Khalid
    Slack, Robert J.
    Brinch, Anne
    Gravelle, Lise
    Morley, Wayne
    Phung, De
    Herman, Kimberly
    Holyer, Ian
    Poulsen, Karen Killerup
    Dogterom, Peter
    Tantawi, Susan
    Zetterberg, Fredrik R.
    Jacoby, Brian
    Schambye, Hans
    Lindmark, Bertil
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 94 (05) : 707 - 720
  • [6] Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants
    Vassilios Aslanis
    Robert J. Slack
    Alison C. MacKinnon
    Catherine McClinton
    Susan Tantawi
    Lise Gravelle
    Ulf J. Nilsson
    Hakon Leffler
    Ashley Brooks
    Sanjeev K. Khindri
    Richard P. Marshall
    Anders Pedersen
    Hans Schambye
    Fredrik Zetterberg
    Cancer Chemotherapy and Pharmacology, 2023, 91 : 267 - 280
  • [7] Characterisation of the novel Galectin-3 inhibitor GB1107 on CCl4-induced liver fibrosis in mice
    MacKinnon, Alison
    Mills, Ross
    Zetterberg, Fredrick
    Slack, Rob
    JOURNAL OF HEPATOLOGY, 2022, 77 : S481 - S481
  • [8] Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants
    Aslanis, Vassilios
    Slack, Robert J.
    MacKinnon, Alison C.
    McClinton, Catherine
    Tantawi, Susan
    Gravelle, Lise
    Nilsson, Ulf J.
    Leffler, Hakon
    Brooks, Ashley
    Khindri, Sanjeev K.
    Marshall, Richard P.
    Pedersen, Anders
    Schambye, Hans
    Zetterberg, Fredrik
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 91 (03) : 267 - 280
  • [9] LPCN 1144 TREATMENT POTENTIAL ASSESSMENT IN A HIGH FAT DIET INDUCED RABBIT MODEL OF HEPATIC FIBROSIS AND NASH
    Kim, Kilyoung
    Chidambaram, Nachiappan
    DelConte, Anthony
    Comeglio, Paolo
    Filippi, Sandra
    Vangara, Kiran
    Frank, Joel
    Papangkorn, Kongnara
    Bruno, Benjamin J.
    Patel, Mahesh V.
    Vignozzi, Linda
    HEPATOLOGY, 2020, 72 : 339A - 339A
  • [10] Galectin-3 Inhibition by A Small-Molecule Inhibitor Reduces Both Pathological Corneal Neovascularization and Fibrosis
    Panjwani, Noorjahan A.
    Cao, Zhiyi
    Chen, Wei-Sheng
    Leffler, Hakon
    Nilsson, Ulf J.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
12345